NASDAQ: ICCCImmucell Corp Stock
$9.71-0.14 (-1.42%)
Updated Sep 14, 2026
ICCC Priceļ»æ
$9.71
Fair Value Price
N/A
Market Capļ»æ
$88.19M
52 Week Lowļ»æ
$4.52
52 Week Highļ»æ
$12.10
P/Eļ»æ
138.71x
P/Bļ»æ
2.81x
P/Sļ»æ
2.97x
PEGļ»æ
3.04x
Dividend Yieldļ»æ
N/A
Revenueļ»æ
$30.68M
Earningsļ»æ
$787.37k
Gross Marginļ»æ
40.3%
Operating Marginļ»æ
2.78%
Profit Marginļ»æ
2.6%
Debt to Equityļ»æ
0.49
Operating Cash Flow
$6M
Betaļ»æ
0.2
Next Earningsļ»æ
N/A
Ex-Dividendļ»æ
N/A
Next Dividendļ»æ
N/A
ICCC Overview
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ICCC's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +28.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ICCC
Ranked#7 of 459
Ranked#7 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.14 | A | |
| $6.85 | A | |
| $41.54 | A |
Be the first to know about important ICCC news, forecast changes, insider trades & much more!
ICCC News
Overview
Due Diligence Score
ā
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ICCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ICCC ($9.71) is trading above its intrinsic value of $1.30, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Valueļ»æ Valuation
ICCC is poor value based on its earnings relative to its share price (138.71x), compared to the US market average (43.6x)
P/E vs Marketļ»æ Valuation
ICCC is poor value based... subscribe to Premium to read more.
P/E vs Industryļ»æ Valuation
There are 30 more ICCC due diligence checks available for Premium users.
Valuation
ICCC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
138.71x
Industry
8.25x
Market
43.6x
ICCC is poor value based... subscribe to Premium to read more.
P/E vs Industryļ»æ Valuation
ICCC is poor value based... subscribe to Premium to read more.
P/E vs Marketļ»æ Valuation
ICCC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.81x
Industry
5.35x
ICCC is good value based... subscribe to Premium to read more.
P/B vs Industryļ»æ Valuation
ICCC price to earnings growth (PEG)
For valuing profitable companies with growth potential
ICCC is poor value relative... subscribe to Premium to read more.
PEG Valueļ»æ Valuation
ICCC's financial health
Profit margin
Revenue
$7.2M
Net Income
$1.8M
Profit Margin
25.5%
ICCC's Earnings (EBIT) of $853.61k... subscribe to Premium to read more.
Interest Coverageļ»æ Financials
ICCC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growthļ»æ Financials
Assets to liabilities
Assets
$46.6M
Liabilities
$15.3M
Debt to equity
0.49
ICCC's short-term assets ($21.08M) exceed... subscribe to Premium to read more.
Short-term Liabilitiesļ»æ Financials
ICCC's short-term assets ($21.08M) exceed... subscribe to Premium to read more.
Long-term Liabilitiesļ»æ Financials
ICCC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debtļ»æ Financials
ICCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equityļ»æ Financials
Cash flow
Operating
$3.0M
Investing
-$733.9k
Financing
-$237.6k
ICCC's operating cash flow ($5.89M)... subscribe to Premium to read more.
Debt Coverageļ»æ Financials
ICCC vs Biotech Stocks
Immucell Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.